The history of Mundipharma can be traced back to 1952 when Mortimer D Sackler, M.D. and Raymond R Sackler, M.D. acquired Prudue based in the US. With these family origins, the company understands the important of long-term business relationships, built on a foundation of trust.

That foundation of trust, along with an entrepreneurial culture and unique approach to partnerships, has given Mundipharma the opportunity to establish a strong market presence that covers the world’s pharmaceutical markets.

  • 1952
    Purdue acquired by the Sackler family in the United States.
  • 1957
    The first Mundipharma entity is founded in Switzerland. This signaled the beginning of Mundipharma’s network of associated companies
  • 1973
    Mundipharma develops a prolonged release technology for the treatment of chronic pain
  • 1992
    Opening of Mundipharma’s operations in Japan
  • 1993
    Opening of Mundipharma's operations in China
  • 1998
    Opening of Mundipharma's operations in South Korea
  • 2004
    Founding of Mundipharma’s Regional Office in Singapore and the beginning of operations in Malaysia
  • 2005
    Beginning of Mundipharma’s operations in the Philippines
  • 2006
    The Mundipharma Oncology division and Research and Development companies were established. Up until 2006, the focus for the Mundipharma network of associated companies was patent controlled formulations such as dihydrocodeine, hydromorphine, morphine, oxycodone and theophylline, in addition to in-licensed products
  • 2012
    Mundipharma launches operations in Indonesia, Hong Kong, Thailand, Vietnam and Taiwan
  • 2013
    Beginning of Mundipharma’s operations in Latin America and the Middle East and North Africa, with regional offices in Brazil and Dubai
  • 2014
    Mundipharma launches operations in Mexico and Egypt
  • NOW
    Now Mundipharma is continuing to grow and is now working on the commercialization of innovative products to manage pain and treat asthma, rheumatiod arthritis and non-Hodgkin’s lymphoma, just to name a few